VIDEO: Real-world data show positive, stable outcomes of faricimab in wet AMD, DME
Click Here to Manage Email Alerts
In this Healio Video Perspective, Arshad M. Khanani, MD, MA, FASRS, speaks about the positive real-world outcomes of faricimab in the TRUCKEE and TAHOE studies, presented at the Euretina congress in Amsterdam.
TRUCKEE in neovascular age-related macular degeneration and TAHOE in diabetic macular edema are independent studies carried out in the U.S. and included both naive and switch patients, with no exclusion criteria. Vabysmo (faricimab, Genentech) showed rapid and stable improvement in all anatomic parameters, with no new safety signals. In a subset of patients, the Notal OCT Analyzer was used for home monitoring and quantification of fluid.
“Faricimab is the first bispecific antibody that’s designed for treatment of retinal diseases. It may give us an additional mechanism of action to get better anatomic outcomes, quick disease control for our patients and hopefully better durability, resulting in decreased treatment burden,” Khanani said.
Collapse
Khanani A. Real-world data for dual pathway inhibition. Presented at: Euretina congress; Oct. 5-8, 2023; Amsterdam.
Read more about
Click Here to Manage Email Alerts